AI and Big Data words are ‘all the rage’ Companies are making a fortune and raising millions in VC funding claiming to do something very new and fancy! All they’re doing is repurposing compounds based on ‘mining’ existing data >> Atomwise/Benevolant/Twoxar/Numedii To do it they’re just using graphical analytics to look for patterns and trends or […]
Big news announcement today NIH to get $414m for Alzheimer’s Research to take total to $1.8bn!!! <<<FUNDING>>>
Looks like Celgene are risking $100 upfront to partner with Prothena’s (Irish Biotech) Tau antibody programme Tau targets are the latest alternative to amyloid They are however ‘edging their bets’ by also putting $100 into Vividion programme to develop new small molecule treatments <<<Celgene>>>
Think we’ve heard this story a thousand time before and every Global pharma Phase III trial has failed with it! I thought they’d realised that targeting AB protein had a basic flaw – that is that some people have amyloid plaques but no AD! >>>Immunological Target<<<
Goedert, De Strooper, Hardy and Haas – leaders in neurological research! I like Hardy’s comment about current treatments being prescribed too late after the onset of the disease It’s unlikely we’ll find a revolutionary treatment but hopefully we’ll make small steps in to slowing the disease in the next few years <<BRAIN>>
Not everything they do is aimed at rare disease <<<Constipation>>
A hot topic with suboxone at the moment Not sure how Adapax (benzhydrocodone and acetaminophen) from Kempharm differentiates itself – especially as still ‘high potential for abuse’ Its just a combination of a couple of old drugs and ‘KemPharm hoping to differentiate its product once it hits the market’ sounds vague But basically its $150m […]
Six biologics to be fast tracked from MedImmune (AZ owned) through a separate company – Viela Bio Inflammatory and auto-immune (incl neuromyelitis) – all rare diseases They’ll make a fortune! All because outside AZ core >>> oncology, respiratory and cardiovascular and metabolic disease (seems pretty broad to me!) J&J situation with Actelion buyout where […]
Is this a Marketeers dream or what! Maybe even an Smartphone app 🙂 <<<DEPRESSION>>>